Professional Documents
Culture Documents
Columbus, OH, November 03, 2020 --(PR.com)-- OrthoNeuro Neurologist Martin T. Taylor, D.O. PhD
has enrolled the first patient in the United States and Australia for a new Parkinson’s disease Phase 3
research trial. The first patient enrolled in the study on Oct. 19 and the second on Oct. 29.
The trial is a subcutaneous Levodopa infusion pump. Participants in the study will help the study team
evaluate if the investigational medication is safe and effective when delivered continuously, 24 hours a
day, through an infusion system. The trial, done at only two sites in Ohio, will include over 130 subjects
across 13 sites in the U.S. and Australia.
“It’s exciting to provide a potential new treatment for patients with advanced Parkinson’s disease,” said
Taylor.
The research trial is through The Orthopedic Foundation. The goal of the trial is to enhance and improve
the motor system of patients with advanced Parkinson’s.
“The Orthopedic Foundation is proud to be a part of Dr. Martin Taylor’s work with advanced Parkinson’s
disease,” said Daryl Sybert, D.O., OrthoNeuro spine surgeon and The Orthopedic Foundation Chairman.
“This groundbreaking research could drastically improve the daily lives for those with this debilitating
disease.”
OrthoNeuro
OrthoNeuro is a dedicated team of orthopedic and neurologic healthcare professionals committed to
providing the highest quality specialty care in Columbus, Ohio and surrounding areas – and doing so with
compassion and understanding. Our board-certified physicians specialize in orthopedic surgery, spine
surgery, neurology, podiatry, physical medicine & rehabilitation. OrthoNeuro currently has 7 locations
throughout greater Columbus. To schedule an appointment, please contact OrthoNeuro at 614-890-6555
or visit the OrthoNeuro website at www.orthoneuro.com.
Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
OrthoNeuro
Heather Benjamin
614-839-2142
Contact via Email
www.orthoneuro.com
Director, Marketing and Communications
News Image:
Page 2/2
PR.com Press Release Distribution Terms of Use